CClinicalTrials.gg
Sign In
CompletedNCT06489691Updated Jan 22, 2026

High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m)

An interventional study of 6-minute walk test (6MWT) in High Altitude Pulmonary Hypertension, sponsored by University of Zurich. Completed at 1 site in Kyrgyzstan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by University of Zurich · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanders with High Altitude Pulmonary Hypertension (HAPH) who permanently live >2500m on 6-minute walk distance (6MWD)

Read the detailed description

This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA >30 mmHg who permanently live at HA >2500 m will perform a 6-minute walk distance test near their living altitude in Aksay at 3200 m and on day 2 and 7 at 760 m after relocation

02

Conditions studied

  • High Altitude Pulmonary Hypertension

Keywords

  • Pulmonary Hypertension
  • Hypoxia
  • High Altitude
  • 6-Minute Walk Test
03

In context

Hypertension, Pulmonary

1,105 studies on the registry are indexed under Hypertension, Pulmonary; 234 are open to participants now.

This study's enrollment of 24 is below the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.

Browse Hypertension, Pulmonary studies →

Lead sponsor

University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Permanently living >2500 m
  • HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Highlanders who cannot follow the study investigations,
  • Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking >20 cigarettes/day or >20 pack-years.
  • Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
  • Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Assessments at 3200 m and 760 m, respectively

    Participants will have a 6-minute walk distance (6MWD) assessment near their resident altitude at 3200 m and after relocation to 760 m after 1 and 7 days.

    Other: 6-minute walk test (6MWT)

Interventions

  • Other6-minute walk test (6MWT)

    6-minute walk test (6MWT) will be performed according to clinical standards

06

What researchers measure

Primary outcomes

  1. 6-minute walk distance (6MWD) on day 2 of relocation to 760 m

    Change in 6MWD in meter between LA (760 m) vs HA (3200 m)

    Time frame: day 2 at 760 m compared to 3200 m

Secondary outcomes

  1. 6-minute walk distance (6MWD) on day 7 of relocation to 760 m

    6-minute walk distance (6MWD) in meter between LA (760 m) and HA (3200 m)

    Time frame: day 7 at 760 m compared to 3200 m

  2. Arterial oxygen saturation by pulseoximetry (SpO2) at rest and at peak 6MWD on day 2 of relocation to 760 m

    Change in SpO2 in % between LA (760 m) vs HA (3200 m)

    Time frame: day 2 at 760 m compared to 3200 m

  3. Arterial oxygen saturation by pulseoximetry (SpO2) at rest and at peak 6MWD on day 7 of relocation to 760 m

    Change in SpO2 in % between LA (760 m) vs HA (3200 m)

    Time frame: day 7 at 760 m compared to 3200 m

  4. Heart rate at rest and at peak 6MWD on day 2 of relocation to 760 m

    Change in hear rate in bpm between LA (760 m) vs HA (3200 m)

    Time frame: after the first night at LA (760 m)

  5. Heart rate at rest and at peak 6MWD on day 7 of relocation to 760 m

    Change in hear rate in bpm between LA (760 m) vs HA (3200 m)

    Time frame: day 7 at 760 m compared to 3200 m

  6. Blood pressure at rest and at 6MWD on day 2 of relocation to 760 m

    Change in blood pressure in mmHg between LA (760 m) vs HA (3200 m)

    Time frame: day 2 at 760 m compared to 3200 m

  7. Blood pressure at rest and at 6MWD on day 7 of relocation to 760 m

    Change in blood pressure in mmHg between LA (760 m) vs HA (3200 m)

    Time frame: day 7 at 760 m compared to 3200 m

  8. Borg Dyspnea scale at end 6MWT on day 2 of relocation to 760 m

    Change of the Borg CR10 dyspnea scale at end of the 6MWT after the first night at LA (760 m) vs HA (3200 m)

    Time frame: day 2 at 760 m compared to 3200 m

  9. Borg Dyspnea scale at end 6MWT on day 7 of relocation to 760 m

    Change of the Borg CR10 dyspnea scale at end of the 6MWT after seven nights at LA (760 m) vs HA (3200 m)

    Time frame: day 7 at 760 m compared to 3200 m

  10. Borg leg fatigue scale at end 6MWT on day 2 of relocation to 760 m

    Change of the Borg CR10 leg fatigue scale at end of the 6MWT after the first night at LA (760 m) vs HA (3200 m)

    Time frame: day 2 at 760 m compared to 3200 m

  11. Borg leg fatigue scale at end 6MWT on day 7 of relocation to 760 m

    Change of the Borg CR10 leg fatigue scale at end of the 6MWT after seven nights at LA (760 m) vs HA (3200 m)

    Time frame: day 7 at 760 m compared to 3200 m

07

Study locations

1 site
  • Aksay Medical Center
    Aksay Plateau, Naryn, Kyrgyzstan, Kyrgyzstan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06489691
Lead sponsor
University of Zurich
Responsible party
Sponsor
First posted
Jul 8, 2024
Start date
Jul 2, 2024
Primary completion
Sep 27, 2024
Completion
Sep 27, 2024
Last update
Jan 22, 2026

Study contacts

Talant M Sooronbaev, Prof. Dr.
principal investigator · National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Silvia Ulrich, Prof. Dr.
principal investigator · University Hospital Zurich, Department of Pulmonology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulmonary edema of mountaineers

Other studies from this sponsor

University of Zurich

Start the discussion